

This listing of the claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently amended) A method of treating ~~patients~~ a patient suffering from severe glaucoma, exhibiting optical nerve head damage and visual field defects, comprising simultaneously administering a combination of IOP reducing agents to the patient's eye.

2. (Original) A method according to claim 1, wherein said combination is administered to the surface of the eye.

B1 3. (Original) A method according to claim 2, wherein said combination is a topical ophthalmic composition comprising a mixture of IOP-reducing agents.

4. (Cancelled).

5. (Currently amended) A method according to claim 1, wherein ~~in~~ improved efficacy in IOP reduction is obtained in ~~severe glaucoma patients~~ the patient when compared to patients suffering from an elevated IOP, but being free from abnormalities in the optical nerve head and visual field loss.

6. (Original) A method according to claim 1, wherein said combination comprises an effective amount of an IOP-reducing agent capable of increasing the uveoscleral outflow of aqueous humor.

7. (Original) A method according to claim 1, wherein said combination comprises an effective amount of an IOP-reducing prostaglandin or a prostaglandin derivative.

8. (Original) A method according to claim 7, wherein said combination comprises an IOP reducing amount of a prostaglandin $F_{2\alpha}$ derivative.

9. (Currently amended) A method according to claim 8, wherein said prostaglandin $F_{2\alpha}$ derivative has an omega chain carrying a ring substituent in a terminal position, selected ~~among~~ from the group consisting of optionally substituted phenyl, cycloalkyl ~~or~~ and aromatic heterocyclic groups.

10. (Original) A method according to claim 9, wherein said prostaglandin $F_{2\alpha}$ is latanoprost or travaprost.

11. (Original) A method according to claim 1, wherein said prostaglandin $F_{2\alpha}$ derivative is isopropyl unoprostone.

12. (Original) A method according to claim 1, wherein said combination comprises an effective amount of an IOP-reducing agent capable of reducing the formation of aqueous humor.

13. (Original) A method according to claim 12, wherein said combination further comprises an effective amount of an IOP-reducing agent capable of increasing the uveoscleral outflow of aqueous humor.

14. (Currently amended) A method according to claim 12, wherein said IOP-reducing agent is selected ~~among~~ from the group consisting of beta-adrenergic agonists and carbonic anhydrase inhibitors.

B1 15. (Original) A method according to claim 14, wherein said combination comprises a prostaglandin F_{2α} derivative and a beta-adrenergic agonist.

16. (Currently amended) A method according to claim 15, wherein said combination comprises a prostaglandin F_{2α} derivative having an omega chain carrying a ring substituent in a terminal position, selected ~~among~~ from the group consisting of optionally substituted phenyl, cycloalkyl ~~or~~ and aromatic heterocyclic groups.

17. (Original) A method according to claim 16, wherein said combination comprises latanoprost and timolol.

18. (Original) A method according to claim 17, wherein said combination is a mixture of latanoprost and timolol in a topical ophthalmic composition.

19. (Currently amended) A method of treating ~~individuals~~ an individual in need of a high IOP-reduction comprising simultaneously administering a combination of IOP reducing agents to the eye.

20. (Currently amended) A method according to claim 19, wherein said ~~individuals have~~ individual has a hereditary disposition for glaucoma.

21. (Currently amended) A method according to claim 19, wherein said ~~individuals suffer~~ individual suffers from complications which may trigger ischemic conditions in the region of the optical nerve head.

22. (Currently amended) A method according to claim 19, wherein said ~~individuals suffer~~ individual suffers ocular hypertension without detected damages of the optical nerve head or a loss of the visual field.

23. (Original) A method according to claim 19, wherein said combination is administered to the surface of the eye.

24. (Original) A method according to claim 21, wherein said combination is a topical ophthalmic composition comprising a mixture of IOP-reducing agents.

25. (Original) A method according to claim 19, wherein said combination comprises an effective amount of an IOP-reducing agent capable of increasing the uveoscleral outflow of aqueous humor.

26. (Original) A method according to claim 19, wherein said combination comprises an effective amount of an IOP-reducing prostaglandin or a prostaglandin derivative.

27. (Original) A method according to claim 26, wherein said combination comprises an IOP reducing amount of a prostaglandin F_{2α} derivative.

B) 28. (Currently amended) A method according to claim 27, wherein said prostaglandin F_{2α} derivative has an omega chain carrying a ring substituent in a terminal position, selected ~~among~~ from the group consisting of optionally substituted phenyl, cycloalkyl ~~or~~ and aromatic heterocyclic groups.

29. (Original) A method according to claim 28, wherein said prostaglandin F_{2α} is latanoprost or travaprost.

30. (Original) A method according to claim 29, wherein said prostaglandin F_{2α} derivative is isopropyl unoprostone.

31. (Original) A method according to claim 19, wherein said combination comprises an effective amount of an IOP-reducing agent capable of reducing the formation of aqueous humor.

32. (Original) A method according to claim 31, wherein said combination further comprises an effective amount of an IOP-reducing agent capable of increasing the uveoscleral outflow of aqueous humor.

33. (Currently amended) A method according to claim 31, wherein said IOP-reducing agent is selected ~~among~~ from the group consisting of beta-adrenergic agonists and carbonic anhydrase inhibitors.

B1 34. (Original) A method according to claim 33, wherein said combination comprises a prostaglandin F_{2α} derivative and a beta-adrenergic agonist.

35. (Currently amended) A method according to claim 34, wherein said combination comprises a prostaglandin F_{2α} derivative having an omega chain carrying a ring substituent in a terminal position, selected ~~among~~ from the group consisting of optionally substituted phenyl, cycloalkyl ~~or~~ and aromatic heterocyclic groups.

36. (Original) A method according to claim 35, wherein said combination comprises latanoprost and timolol.

37. (Original) A method according to claim 36, wherein said combination is a mixture of latanoprost and timolol in a topical ophthalmic composition.

38.-75. (Canceled).

B1 76. (New) A method according to claim 19, wherein the individual exhibits optical nerve head damage and visual field defects.
